The DOI matches its Crossref record; 101 of the 101 references it cites were found in a registry or an index.
Human Metabolites of Cannabidiol: A Review on Their Formation, Biological Activity, and Relevance in Therapy
Open accessAbstract
Cannabidiol (CBD), the main nonpsychoactive constituent of Cannabis sativa, has shown a wide range of therapeutically promising pharmacological effects either as a sole drug or in combination with other drugs in adjunctive therapy. However, the targets involved in the therapeutic effects of CBD appear to be elusive. Furthermore, scarce information is available on the biological activity of its human metabolites which, when formed in pharmacologically relevant concentration, might contribute to or even account for the observed therapeutic effects. The present overview summarizes our current knowledge on the pharmacokinetics and metabolic fate of CBD in humans, reviews studies on the biological activity of CBD metabolites either in vitro or in vivo, and discusses relevant drug–drug interactions. To facilitate further research in the area, the reported syntheses of CBD metabolites are also catalogued.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Isolation, Structure, and Partial Synthesis of an Active Constituent of Hashish
Gaoni, Y., & Mechoulam, R. (1964) · Journal of the American Chemical Society · doi:10.1021/ja01062a046 · Cited by 2,393
Bisogno, T., Hanuš, L., De Petrocellis, L., Tchilibon, S., Ponde, D. E., Brandi, I., Moriello, A. S., Davis, J. B., Mechoulam, R., & Di Marzo, V. (2001) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704327 · Cited by 1,311
Self-citationHuman Cannabinoid Pharmacokinetics
Huestis, M. A. (2007) · Chemistry & Biodiversity · doi:10.1002/cbdv.200790152 · Cited by 1,102
Devinsky, O., Cilio, M. R., Cross, H., Fernandez‐Ruiz, J., French, J., Hill, C., Katz, R., Di Marzo, V., Jutras‐Aswad, D., Notcutt, W. G., et al. (2014) · Epilepsia · doi:10.1111/epi.12631 · Cited by 1,000
Mathur, R. (2004) · Drug Screening Methods · doi:10.5005/jp/books/10243_6 · Cited by 665
Molecular Targets of Cannabidiol in Neurological Disorders
Ibeas Bih, C., Chen, T., Nunn, A. V. W., Bazelot, M., Dallas, M., & Whalley, B. J. (2015) · Neurotherapeutics · doi:10.1007/s13311-015-0377-3 · Cited by 578
Cannabidiol (CBD) and its analogs: a review of their effects on inflammation.
Burstein, S. (2015) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2015.01.059 · Cited by 573
Safety and side effects of cannabidiol, a Cannabis sativa constituent
Machado Bergamaschi, M., Helena Costa Queiroz, R., Waldo Zuardi, A., & Alexandre S. Crippa, J. (2011) · Current Drug Safety · doi:10.2174/157488611798280924 · Cited by 558
McPartland, J. M., Duncan, M., Di Marzo, V., & Pertwee, R. G. (2015) · British Journal of Pharmacology · doi:10.1111/bph.12944 · Cited by 521
Mechoulam, R., Peters, M., Murillo‐Rodriguez, E., & Hanuš, L. O. (2007) · Chemistry & Biodiversity · doi:10.1002/cbdv.200790147 · Cited by 515
Drug–drug interaction between clobazam and cannabidiol in children with refractory epilepsy
Geffrey, A. L., Pollack, S. F., Bruno, P. L., & Thiele, E. A. (2015) · Epilepsia · doi:10.1111/epi.13060 · Cited by 496
Mechoulam, R., & Shvo, Y. (1963) · Tetrahedron · doi:10.1016/0040-4020(63)85022-x · Cited by 486
Fusar-Poli, P., Crippa, J. A., Bhattacharyya, S., Borgwardt, S. J., Allen, P., Martin-Santos, R., Seal, M., Surguladze, S. A., O’Carrol, C., Atakan, Z., et al. (2009) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2008.519 · Cited by 465
Deiana, S., Watanabe, A., Yamasaki, Y., Amada, N., Arthur, M., Fleming, S., Woodcock, H., Dorward, P., Pigliacampo, B., Close, S., et al. (2012) · Psychopharmacology · doi:10.1007/s00213-011-2415-0 · Cited by 398
Pertwee, R. G. (1977) · Neuroscience · doi:10.1016/0306-4522(77)90080-x · Cited by 382
Fernández‐Ruiz, J., Sagredo, O., Pazos, M. R., García, C., Pertwee, R., Mechoulam, R., & Martínez‐Orgado, J. (2013) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2012.04341.x · Cited by 349
Stout, S. M., & Cimino, N. M. (2014) · Drug Metabolism Reviews · doi:10.3109/03602532.2013.849268 · Cited by 347
Jiang, R., Yamaori, S., Takeda, S., Yamamoto, I., & Watanabe, K. (2011) · Life Sciences · doi:10.1016/j.lfs.2011.05.018 · Cited by 322
Controlled clinical trial of cannabidiol in Huntington's disease
Consroe, P., Laguna, J., Allender, J., Snider, S., Stern, L., Sandyk, R., Kennedy, K., & Schram, K. (1991) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(91)90386-g · Cited by 320
Structure of Cannabidiol, a Product Isolated from the Marihuana Extract of Minnesota Wild Hemp. I
Adams, R., Hunt, M., & Clark, J. H. (1940) · Journal of the American Chemical Society · doi:10.1021/ja01858a058 · Cited by 298
Cannabidiol exerts sebostatic and antiinflammatory effects on human sebocytes
Oláh, A., Tóth, B. I., Borbíró, I., Sugawara, K., Szöllõsi, A. G., Czifra, G., Pál, B., Ambrus, L., Kloepper, J., Camera, E., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci64628 · Cited by 268
Cannabidiol—transdermal delivery and anti-inflammatory effect in a murine model
Lodzki, M., Godin, B., Rakou, L., Mechoulam, R., Gallily, R., & Touitou, E. (2003) · Journal of Controlled Release · doi:10.1016/j.jconrel.2003.09.001 · Cited by 268
Cannabidiol: an overview of some chemical and pharmacological aspects. Part I: chemical aspects
Mechoulam, R., & Hanuš, L. (2002) · Chemistry and Physics of Lipids · doi:10.1016/s0009-3084(02)00144-5 · Cited by 250
Self-citationOhlsson, A., Lindgren, J.-E., Andersson, S., Agurell, S., Gillespie, H., & Hollister, L. E. (1986) · Biological Mass Spectrometry · doi:10.1002/bms.1200130206 · Cited by 239
Gloss, D., & Vickrey, B. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009270.pub3 · Cited by 231
Karschner, E. L., Darwin, W. D., Goodwin, R. S., Wright, S., & Huestis, M. A. (2011) · Clinical Chemistry · doi:10.1373/clinchem.2010.152439 · Cited by 231
Cannabidiol as potential anticancer drug
Massi, P., Solinas, M., Cinquina, V., & Parolaro, D. (2013) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2012.04298.x · Cited by 230
Constituents of Cannabis Sativa
ElSohly, M. A., & Gul, W. (2014) · Handbook of Cannabis · doi:10.1093/acprof:oso/9780199662685.003.0001 · Cited by 220
(2014) · Oxford University Press eBooks · doi:10.1093/acprof:oso/9780199662685.001.0001 · Cited by 219
Biochemistry and Physiology of Substance Abuse
WATSON, R. R. (1990) · Medical Entomology and Zoology · Cited by 202
Cannabidiol Is a Potent Inhibitor of the Catalytic Activity of Cytochrome P450 2C19
Jiang, R., Yamaori, S., Okamoto, Y., Yamamoto, I., & Watanabe, K. (2013) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.dmpk-12-rg-129 · Cited by 199
Cannabidiol in Humans—The Quest for Therapeutic Targets
Zhornitsky, S., & Potvin, S. (2012) · Pharmaceuticals · doi:10.3390/ph5050529 · Cited by 197
Characterization of P-glycoprotein Inhibition by Major Cannabinoids from Marijuana
Zhu, H.-J., Wang, J.-S., Markowitz, J. S., Donovan, J. L., Gibson, B. B., Gefroh, H. A., & DeVane, C. L. (2006) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.098541 · Cited by 192
Cannabidiol monotherapy for treatment-resistant schizophrenia
Zuardi, A. W., Hallak, J. E. C., Dursun, S. M., Morais, S. L., Sanches, R. F., Musty, R. E., & Crippa, J. A. S. (2006) · Journal of Psychopharmacology · doi:10.1177/0269881106060967 · Cited by 192
Nadulski, T., Pragst, F., Weinberg, G., Roser, P., Schnelle, M., Fronk, E.-M., & Stadelmann, A. M. (2005) · Therapeutic Drug Monitoring · doi:10.1097/01.ftd.0000177223.19294.5c · Cited by 185
Mazur, A., Lichti, C. F., Prather, P. L., Zielinska, A. K., Bratton, S. M., Gallus‐Zawada, A. E., Finel, M., Miller, G. P., Radominska-p, A., & Moran, J. H. (2009) · Drug Metabolism and Disposition · doi:10.1124/dmd.109.026898 · Cited by 168
Cannabinoids and appetite stimulation
Mattes, R. D., Engelman, K., Shaw, L. M., & Elsohly, M. A. (1994) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(94)90475-8 · Cited by 163
Pharmacologically Active Drug Metabolites: Impact on Drug Discovery and Pharmacotherapy
Obach, R. S. (2013) · Pharmacological Reviews · doi:10.1124/pr.111.005439 · Cited by 159
Cannabidiol bioavailability after nasal and transdermal application: effect of permeation enhancers
Paudel, K. S., Hammell, D. C., Agu, R. U., Valiveti, S., & Stinchcomb, A. L. (2010) · Drug Development and Industrial Pharmacy · doi:10.3109/03639041003657295 · Cited by 143
Manini, A. F., Yiannoulos, G., Bergamaschi, M. M., Hernandez, S. H., Olmedo, R., Barnes, A. J., Winkel, G. H., Sinha, R., Jutras‐Aswad, D., Huestis, M. A., et al. (2015) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000118 · Cited by 139
Stott, C. G., White, L., Wright, S., Wilbraham, D., & Guy, G. W. (2013) · SpringerPlus · doi:10.1186/2193-1801-2-236 · Cited by 136
Brenneisen, R., Egli, A., ElSohly, M. A., Henn, V. S., & Spiess, Y. (1996) · PubMed · Cited by 134
Paton, W. D. M., & Pertwee, R. G. (1972) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1972.tb07261.x · Cited by 133
A phase I study to assess the single and multiple dose pharmacokinetics of THC/CBD oromucosal spray
Stott, C. G., White, L., Wright, S., Wilbraham, D., & Guy, G. W. (2012) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-012-1441-0 · Cited by 131
Agurell, S., Carlsson, S., Lindgren, J. E., Ohlsson, A., Gillespie, H., & Hollister, L. (1981) · Experientia · doi:10.1007/bf02085029 · Cited by 129
Human skin permeation of Δ8-tetrahydrocannabinol, cannabidiol and cannabinol
Stinchcomb, A. L., Valiveti, S., Hammell, D. C., & Ramsey, D. R. (2004) · Journal of Pharmacy and Pharmacology · doi:10.1211/0022357022791 · Cited by 127
The effects of pharmaceutical excipients on drug disposition
Buggins, T. R., Dickinson, P. A., & Taylor, G. (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.08.017 · Cited by 125
Medicinal uses of cannabis and cannabinoids.
Guy, G. W., Whittle, B. A., & Robson, P. (2004) · Cited by 123
Sachse-Seeboth, C., Pfeil, J., Sehrt, D. B., Meineke, I., Tzvetkov, M. V., Bruns, E., Poser, W., Vormfelde, S. V., & Brockmöller, J. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2008.213 · Cited by 105
Enantiomeric cannabidiol derivatives: synthesis and binding to cannabinoid receptors
Hanu, L. O., Tchilibon, S., Ponde, D. E., Breuer, A., Fride, E., & Mechoulam, R. (2005) · Organic & Biomolecular Chemistry · doi:10.1039/b416943c · Cited by 104
Self-citationInteraction of plant cannabinoids with the multidrug transporter ABCC1 (MRP1)
Holland, M. L., Allen, J. D., & Arnold, J. C. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.06.079 · Cited by 102
Metabolites of cannabidiol identified in human urine
Harvey, D. J., & Mechoulam, R. (1990) · Xenobiotica · doi:10.3109/00498259009046849 · Cited by 101
Consroe, P. F., Kennedy, K., & Schram, K. H. (1991) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(91)90357-8 · Cited by 85
Bornheim, L. M., & Grillo, M. P. (1998) · Chemical Research in Toxicology · doi:10.1021/tx9800598 · Cited by 83
Watanabe, K., Itokawa, Y., Yamaori, S., et al. (2007) · Forensic Toxicology · doi:10.1007/s11419-007-0021-y · Cited by 81
A preliminary investigation on the distribution of cannabinoids in man
Gronewold, A., & Skopp, G. (2011) · Forensic Science International · doi:10.1016/j.forsciint.2011.04.010 · Cited by 81
Shani, A., & Mechoulam, R. (1974) · Tetrahedron · doi:10.1016/s0040-4020(01)97114-5 · Cited by 79
Cannabidiol changes P-gp and BCRP expression in trophoblast cell lines
Feinshtein, V., Erez, O., Ben‐Zvi, Z., Erez, N., Eshkoli, T., Sheizaf, B., Sheiner, E., Huleihel, M., & Holcberg, G. (2013) · PeerJ · doi:10.7717/peerj.153 · Cited by 77
Pharmaceutical Excipients Influence the Function of Human Uptake Transporting Proteins
Engel, A., Oswald, S., Siegmund, W., & Keiser, M. (2012) · Molecular Pharmaceutics · doi:10.1021/mp3001815 · Cited by 73
HU-331, a novel cannabinoid-based anticancer topoisomerase II inhibitor
Kogan, N. M., Schlesinger, M., Priel, E., Rabinowitz, R., Berenshtein, E., Chevion, M., & Mechoulam, R. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0039 · Cited by 68
Eichler, M., Spinedi, L., Unfer-Grauwiler, S., Bodmer, M., Surber, C., Luedi, M. M., & Drewe, J. (2012) · Planta Medica · doi:10.1055/s-0031-1298334 · Cited by 67
Distribution of free and conjugated cannabinoids in human bile samples
Fabritius, M. M., Staub, C., Mangin, P. J., & Giroud, C. (2012) · Forensic Science International · doi:10.1016/j.forsciint.2012.08.013 · Cited by 67
Metabolic and psychophysiologic studies of cannabidiol-hexobarbital interaction
Benowitz, N. L., Nguyen, T., Jones, R. T., Herning, R. I., & Bachman, J. (1980) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1980.139 · Cited by 67
Characterization of cannabidiol-mediated cytochrome P450 inactivation
Bornheim, L. M., Everhart, E. T., Li, J., & Correia, M. A. (1993) · Biochemical Pharmacology · doi:10.1016/0006-2952(93)90286-6 · Cited by 64
Mechoulam, R., Ben‐Zvi, Z., & Gaoni, Y. (1968) · Tetrahedron · doi:10.1016/0040-4020(68)88159-1 · Cited by 63
Bornheim, L. M., Kim, K. Y., Chen, B. L., & Correia, M. A. (1993) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1993.2541 · Cited by 63
Guy, G. W., & Flint, M. (2004) · Journal of Cannabis Therapeutics · doi:10.1300/j175v03n03_03 · Cited by 62
(+)-Cannabidiol analogues which bind cannabinoid receptors but exert peripheral activity only
Fride, E., Feigin, C., Ponde, D. E., Breuer, A., Hanuš, L., Arshavsky, N., & Mechoulam, R. (2004) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2004.10.049 · Cited by 62
Self-citationMass spectrometry of the cannabinoids and their metabolites
Harvey, D. J. (1987) · Mass Spectrometry Reviews · doi:10.1002/mas.1280060104 · Cited by 57
Jacob, A. G., & Todd, A. R. (1940) · Journal of the Chemical Society (Resumed) · doi:10.1039/jr9400000649 · Cited by 55
Nye, J. S., Seltzman, H. H., Pitt, C. G., & Snyder, S. H. (1985) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)23705-3 · Cited by 54
Gloss, D. S., & Vickrey, B. G. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009270.pub2 · Cited by 52
ElSohly, M. A., Harland, E. C., Benigni, D. A., & Waller, C. W. (1984) · Current Eye Research · doi:10.3109/02713688409000797 · Cited by 51
Synthesis of Cannabidiols via Alkenylation of Cyclohexenyl Monoacetate
Kobayashi, Y., Takeuchi, A., & Wang, Y. (2006) · Organic Letters · doi:10.1021/ol060692h · Cited by 51
CB2 and TRPV1 receptors mediate cannabinoid actions on MDR1 expression in multidrug resistant cells
Arnold, J. C., Hone, P., Holland, M. L., & Allen, J. D. (2012) · Pharmacological Reports · doi:10.1016/s1734-1140(12)70871-x · Cited by 50
Known Pharmacological Actions of Nine Nonpsychotropic Phytocannabinoids
Cascio, M. G., & Pertwee, R. G. (2014) · Oxford University Press eBooks · doi:10.1093/acprof:oso/9780199662685.003.0007 · Cited by 46
Fride, E., Ponde, D. E., Breuer, A., & Hanuš, L. (2005) · Neuropharmacology · doi:10.1016/j.neuropharm.2005.01.023 · Cited by 44
Self-citationImpact of enzymatic and alkaline hydrolysis on CBD concentration in urine
Bergamaschi, M. M., Barnes, A. J., Queiróz, R. H. C., Hurd, Y. L., & Huestis, M. A. (2013) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-013-6837-x · Cited by 43
Alozie, S. O., Martin, B. R., Harris, L. S., & Dewey, W. L. (1980) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(80)90359-7 · Cited by 43
ULISS, D. B., Razdan, R. K., & Dalzell, H. C. (1974) · Journal of the American Chemical Society · doi:10.1021/ja00830a045 · Cited by 43
Hartsel, S. C., Loh, W., & Robertson, L. (1983) · Planta Medica · doi:10.1055/s-2007-969870 · Cited by 43
Yamaori, S., Kinugasa, Y., Jiang, R., Takeda, S., Yamamoto, I., & Watanabe, K. (2015) · Life Sciences · doi:10.1016/j.lfs.2015.07.007 · Cited by 42
Synthesis of a Primary Metabolite of Cannabidiol
Tchilibon, S., & Mechoulam, R. (2000) · Organic Letters · doi:10.1021/ol006369a · Cited by 42
Anticonvulsant activity of four oxygenated cannabidiol derivatives.
Carlini, E. A., Mechoulam, R., & Lander, N. (1975) · PubMed · Cited by 39
Induction and genetic regulation of mouse hepatic cytochrome P450 by cannabidiol
Bornheim, L. M., Everhart, E. T., Li, J., & Correia, M. A. (1994) · Biochemical Pharmacology · doi:10.1016/0006-2952(94)90236-4 · Cited by 39
Küppers, F. J. E. M., Lousberg, R. J. J. C., Bercht, C. A. L., Salemink, C. A., Terlouw, J. K., Heerma, W., & LAVEN, A. (1973) · Tetrahedron · doi:10.1016/s0040-4020(01)93404-0 · Cited by 36
Harvey, D. J., Samara, E. E., & Mechoulam, R. (1991) · Journal of Chromatography B Biomedical Sciences and Applications · doi:10.1016/0378-4347(91)80587-3 · Cited by 34
Total syntheses of cannabidiol and Δ 1 -tetrahydrocannabinol metabolites
Lander, N., Ben‐Zvi, Z., Mechoulam, R., Martin, B. R., Nordqvist, M., & Agurell, S. (1976) · Journal of the Chemical Society Perkin Transactions 1 · doi:10.1039/p19760000008 · Cited by 32
Wu, H., & Jan, T. (2010) · Toxicology Letters · doi:10.1016/j.toxlet.2010.02.012 · Cited by 32
Cannabielsoin as a new metabolite of cannabidiol in mammals
Yamamoto, I., GOHDA, H., Narimatsu, S., Watanabe, K., & Yoshimura, H. (1991) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(91)90360-e · Cited by 32
Kozela, E., Haj, C. G., Hanuš, L., Chourasia, M., Shurki, A., Juknat, A., Kaushansky, N., Mechoulam, R., & Vogel, Z. (2016) · Chemical Biology and Drug Design · doi:10.1111/cbdd.12637 · Cited by 30
Self-citationHU-444, a Novel, Potent Anti-Inflammatory, Nonpsychotropic Cannabinoid
Haj, C. G., Sumariwalla, P. F., Hanuš, L., Kogan, N. M., Yektin, Z., Mechoulam, R., Feldmann, M., & Gallily, R. (2015) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.115.226100 · Cited by 26
Self-citationYamamoto, I., GOHDA, H., Narimatsu, S., & Yoshimura, H. (1988) · Journal of Pharmacobio-Dynamics · doi:10.1248/bpb1978.11.833 · Cited by 26
Marihuana: Harvey Lecture, February 19, 1942.
ADAMS, R. L. P. (1942) · PubMed · Cited by 26
Microbiological oxidation of the pentyl side chain of cannabinoids
Robertson, L. W., Koh, S. W., HUFF, S. R., Malhotra, R. K., & Ghosh, A. (1978) · Cellular and Molecular Life Sciences · doi:10.1007/bf01915321 · Cited by 21
Identification of glucose conjugates as major urinary metabolites of cannabidiol in the dog
Samara, E. E., Bialer, M., & Harvey, D. J. (1990) · Xenobiotica · doi:10.3109/00498259009047153 · Cited by 20
Harvey, D. J., Martin, B. R., & Paton, W. D. M. (1978) · Springer eBooks · doi:10.1007/978-1-4613-3991-5_13 · Cited by 13
Cannabinoid Pharmacokinetics and Disposition in Alternative Matrices
Huestis, M. A., & Smith, M. L. (2014) · Oxford University Press eBooks · doi:10.1093/acprof:oso/9780199662685.003.0016 · Cited by 13
Yamamoto, I., GOHDA, H., Narimatsu, S., et al. (1989) · Journal of Pharmacobio-Dynamics · doi:10.1248/bpb1978.12.488 · Cited by 12
Harvey, D. J., & Brown, N. K. (1990) · Journal of Mass Spectrometry · doi:10.1002/bms.1200190907 · Cited by 7
Total synthesis of cannabidiol and delta1-tetrahydrocannabinol metabolites.
Lander, N., Ben‐Zvi, Z., Mechoulam, R., Martin, B. R., Nordqvist, M., & Agurell, S. (1976) · PubMed · Cited by 6
Cited by
Phytocannabinoids: a unified critical inventory
Hanuš, L. O., Meyer, S. M., Muñoz, E., Taglialatela-Scafati, O., & Appendino, G. (2016) · Natural Product Reports · doi:10.1039/c6np00074f · Cited by 844
Self-citationThe pharmacokinetics and the pharmacodynamics of cannabinoids
Lucas, C. J., Galettis, P., & Schneider, J. (2018) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13710 · Cited by 724
Practical considerations in medical cannabis administration and dosing
MacCallum, C. A., & Russo, E. B. (2018) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2018.01.004 · Cited by 663
Iffland, K., & Grotenhermen, F. (2017) · Cannabis & Cannabinoid Research · doi:10.1089/can.2016.0034 · Cited by 645
Cannabidiol Adverse Effects and Toxicity
Huestis, M. A., Solimini, R., Pichini, S., Pacifici, R., Carlier, J., & Busardò, F. P. (2019) · Current Neuropharmacology · doi:10.2174/1570159x17666190603171901 · Cited by 468
Metadata
- Authors
- Ujváry, I., & Hanuš, L.
- Venue
- Cannabis and Cannabinoid Research
- Publisher
- SAGE Publications
- Published
- 2016-12
- Volume
- 1
- Issue
- 1
- Pages
- 90-101
- ISSN
- 2378-8763 (ISSN-L)
- OpenAlex
- W2309274031
- Cited by
- 298
- References
- 101
- FWCI
- 11.35
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.